基线免疫状态与T细胞克隆动力学与大B细胞淋巴瘤CAR-T疗法持久缓解相关
该研究对50例接受阿基仑赛治疗的大B细胞淋巴瘤患者系列外周血样本整合单细胞RNA与T细胞受体测序、流式及质谱流式分析,发现应答者预处理时B细胞存在及ALC/AMC升高,输注产物富集克隆扩增的高活化CD8+ T细胞;在ZUMA-1队列99例中验证,基线B细胞比例≥0.5%且ALC/AMC≥1.2构建的两因素模型可预测无进展生存。
要点
- 应答者预处理时存在B细胞且ALC/AMC升高。
- 应答者输注产物富集克隆扩增的高活化CD8+ T细胞。
- ZUMA-1队列中基线B细胞升高者80%为完全缓解。
核心结论
- 患者基线免疫状态通过调节T细胞采集物组成及促进更有利的循环免疫环境,影响CAR-T应答可能性。
- 这些基线免疫特征可在临床中于CAR-T前便捷检测,用于预测治疗应答。
研究设计与样本
- 研究分析50例接受阿基仑赛治疗的LBCL患者从采集日(第-28天/基线)至CAR-T输注后28天的系列外周血样本。
- 整合单细胞RNA与T细胞受体测序、流式细胞术及质谱流式细胞术。
- 将观察扩展至ZUMA-1队列的99例患者。
主要发现
- 与应答相关的预处理患者特征包括存在B细胞及绝对淋巴细胞计数与绝对单核细胞计数比值(ALC/AMC)升高。
- 应答者的输注产物富集克隆扩增、高度活化的CD8+ T细胞。
- ZUMA-1队列中识别出基线B细胞升高的一部分患者,其中80%为完全缓解者。
- 将B细胞比例≥0.5%与ALC/AMC≥1.2整合为两因素预测模型并应用于ZUMA-1队列。
- 满足1项或2项标准者1年估计无进展生存率为65%,而两项均不满足者为31%。
关键数值与推荐
- B细胞比例≥0.5%与ALC/AMC≥1.2构成两因素预测模型。
- 满足1项或2项标准者1年估计无进展生存率65% vs 两项均不满足者31%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T cells (CAR-Ts) has revolutionized outcomes for patients with relapsed/refractory large B-cell lymphoma (LBCL), but the cellular and molecular features associated with response remain largely unresolved. We analyzed serial peripheral blood samples ranging from the day of apheresis (day -28/baseline) to 28 days after CAR-T infusion from 50 patients with LBCL treated with axicabtagene ciloleucel by integrating single-cell RNA and T-cell receptor sequencing, flow cytometry, and mass cytometry to characterize features associated with response to CAR-T. Pretreatment patient characteristics associated with response included the presence of B cells and increased absolute lymphocyte count to absolute monocyte count ratio (ALC/AMC). Infusion products from responders were enriched for clonally expanded, highly activated CD8+ T cells. We expanded these observations to 99 patients from the ZUMA-1 cohort and identified a subset of patients with elevated baseline B cells, 80% of whom were complete responders. We integrated B-cell proportion ≥0.5% and ALC/AMC ≥1.2 into a 2-factor predictive model and applied this model to the ZUMA-1 cohort. Estimated progression-free survival at 1 year in patients meeting 1 or both criteria was 65% vs 31% for patients meeting neither criterion. Our results suggest that patients' immunologic state at baseline affects the likelihood of response to CAR-T through both modulation of the T-cell apheresis product composition and promoting a more favorable circulating immune compartment before therapy. These baseline immunologic features, measured readily in the clinical setting before CAR-T, can be applied to predict response to therapy.
引用
- Maurer K, Grabski IN, Houot R, et al. Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma. Blood. 2024. PMID: 39241199. doi:10.1182/blood.2024024381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。